Bad Homburg, April 2026 — After four days of intensive scientific exchange, the TFmed – Therapeutic Frontiers in Medicine: Mechanisms and Modalities conference successfully concluded, highlighting the critical role of collaboration in advancing translational medicine.

Co‑organized by curATime – Cluster for Atherothrombosis and Individualized Medicine, PROXIDRUGS, and CNATM – Cluster for Nucleic Acid Therapeutics Munich, TFmed 2026 demonstrated the strength of cross‑cluster cooperation in addressing complex biomedical challenges and accelerating the translation of innovative research into clinical applications.

TFmed brought together researchers from academia, clinical practice, and industry, providing an interdisciplinary forum for presenting cutting‑edge research, discussing emerging therapeutic approaches, and exploring novel modalities. The diverse scientific program reflected the breadth of current translational research, spanning molecular mechanisms, therapeutic development, and clinical perspectives.

Beyond the high‑level scientific presentations, TFmed fostered open dialogue, informal discussions, and networking opportunities that enabled participants to exchange ideas, initiate new collaborations, and strengthen existing partnerships. This dynamic atmosphere underlined the importance of intensive scientific interaction for driving innovation and impactful translational research.

By connecting expertise across clusters and disciplines, TFmed 2026 once again positioned itself as a key platform for shaping the future of translational medicine and advancing therapies that have the potential to improve patient care.

Conference website:
https://tfmed-conference.org